Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267613 · ClinicalTrials.gov registry record · Phase 3
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
A Phase 3 study of Erosive Esophagitis, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT05267613 is a Phase 3 study of Erosive Esophagitis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 50 participants, below the 202-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05267613, a Phase 3 study of Erosive Esophagitis, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Conditions Studied
Interventions
- DRUG Nexium 20mg
- DRUG Nexium 10mg
Study Locations (20)
Other
- Research Site - Córdoba
- Research Site - Córdoba
- Research Site - Paraná
- Research Site - Rosario
California
- Research Site - Fontana
- Research Site - Orange
- Research Site - Sacramento
Florida
- Research Site - Miami
- Research Site - Orlando
Ohio
- Research Site - Akron
- Research Site - Cleveland
Alabama
- Research Site - Mobile
Illinois
- Research Site - Downers Grove
Indiana
- Research Site - Carmel
Massachusetts
- Research Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05267613
The ClinicalTrials.gov registry entry for NCT05267613 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (75% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erosive Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Nexium 20mg is the first listed.
NCT05267613 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05267613 about?
NCT05267613 is a clinical study titled "Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.". The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
What is the current status of trial NCT05267613?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-07-01. Estimated completion is 2027-09-06.
What conditions does trial NCT05267613 study?
This clinical trial studies the following conditions: Erosive Esophagitis.
What interventions are being tested in trial NCT05267613?
The interventions under investigation include: Nexium 20mg (DRUG), Nexium 10mg (DRUG).
Who is sponsoring clinical trial NCT05267613?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05267613 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erosive Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
RECRUITING · Phase 2
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
-
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
COMPLETED · Phase 4
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
COMPLETED · Phase 2
-
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.